BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 31, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

April 28, 2022

View Archived Issues
Heart.png

Medtronic strikes $50M deal for Acutus heart device portfolio

Acutus Medical Inc. is selling its left-heart access portfolio to Medtronic plc in a deal worth upwards of $50 million. The portfolio of devices includes a line of sheath-compatible septal crossing devices and steerable sheaths. Under the terms of the agreement, Medtronic will make an upfront cash payment to Acutus of $50 million and additional undisclosed payments based on milestones and future sales. Read More
FDA-sign.png

Califf: Commissioner turnover a destabilizing force at US FDA

In his second stint as U.S. FDA commissioner, Robert Califf discussed the challenges in leading a massive agency that has seen seven commissioners come and go over the past 10 years. Read More
china-mask-coronavirus.png

Med-tech industry so far minimally affected by China shutdowns

With one-quarter of China’s population affected by rolling shutdowns, manufacturers worldwide are preparing for a summer of supply chain nightmares. Shanghai and its normally bustling port have been closed now for a month and the nation’s COVID-Zero policy is now threatening Beijing. So far, though, the med-tech industry remains minimally affected, but the coming months may tell a different story. Read More

Arecor eyes fast development for concentrated insulin product after phase I readout

Arecor Therapeutics plc has presented early stage clinical data from a novel concentrated insulin formulation, which it hopes will outperform marketed rivals by allowing lower volume and reduced frequency doses. Cambridge, U.K.-based Arecor presented data at the International Advanced Technologies and Treatments for Diabetes meeting from AT-278, an investigational meal-time concentrated (500 U/mL) novel formulation of insulin. Read More
Multiple sclerosis

Study finds targets of T-cell response in multiple sclerosis

Screening a panel of potential autoantigens, investigators at the Karolinska Institute have identified four autoantigens that are targeted by the T cells of multiple sclerosis patients. Read More

Appointments and advancements for April 28, 2022

New hires and promotions in the med-tech industry, including: Accuray, Cardiex, Cytek Biosciences, Truepill. Read More

Financings for April 28, 2022

Med-tech firms raising money in public or private financings, including: Notisphere. Read More

In the clinic for April 28, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acroviz, Diabeloop. Read More

Other news to note for April 28, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anelto, Biointellisense, CMR Surgical, Delpor, CODICO, Eli Lilly, Iterative Scopes, Philips, Piezo Motion, Prisma Health, Think Surgical. Read More

Regulatory actions for April 28, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Nano-X, Nocira, Onera, Transmedics. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 30, 2026.
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Vials, syringes, and pills

    With improved technologies, biomarkers, failed drugs may come into their own

    BioWorld
    At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing